Ozempic vs Mounjaro
The two most prescribed GLP-1 medications compared by brand. Which is better for weight loss, and what your doctor won't tell you about off-label use.
💊 Ozempic
- Generic Name
Semaglutide - Manufacturer
Novo Nordisk - FDA Indication
Type 2 Diabetes - Weight Loss Use
Off-label (Wegovy = approved) - Mechanism
GLP-1 receptor agonist - Max Dose
2 mg/week (Ozempic) - Key Trial
STEP 1: 14.9% weight loss - Cost (Cash)
$900–$1,200/mo
💊 Mounjaro
- Generic Name
Tirzepatide - Manufacturer
Eli Lilly - FDA Indication
Type 2 Diabetes - Weight Loss Use
Off-label (Zepbound = approved) - Mechanism
Dual GLP-1/GIP agonist - Max Dose
15 mg/week - Key Trial
SURMOUNT-1: 22.5% weight loss - Cost (Cash)
$1,000–$1,200/mo
🔑 Key Distinction: Brand Names vs Active Ingredients
This is where most people get confused. Ozempic and Wegovy are both semaglutide — same drug, different doses and FDA approvals. Mounjaro and Zepbound are both tirzepatide — same relationship. Ozempic is technically for diabetes; many doctors prescribe it off-label for weight loss because Wegovy has been harder to get.
Weight Loss Comparison
⚠️ Important Context
Ozempic's max dose is 2 mg (for T2D). Wegovy goes up to 2.4 mg (for weight loss). The STEP 1 trial used the 2.4 mg Wegovy dose. If you're on Ozempic at 1–2 mg for weight loss, your results may differ from the trial numbers above.
Side Effects
Insurance & Access
This is often the deciding factor for most patients:
- Insurance coverage varies widely. Some plans cover Ozempic but not Mounjaro, or vice versa. Check your formulary first.
- Manufacturer savings cards from both Novo Nordisk and Eli Lilly can bring copays to $25/month for eligible commercially insured patients.
- Compounded semaglutide has been available through telehealth at ~$150–$400/month. FDA compounding rules have been shifting — check current availability.
- Supply shortages have affected both brands intermittently since 2023. Mounjaro supply has generally been more stable.
⚖️ Who Should Choose What?
- Your insurance covers it and not Mounjaro
- You want an oral option (Rybelsus) — no oral tirzepatide yet
- Compounded semaglutide is available and cost is your main concern
- You prefer the longer safety track record
- Maximum weight loss is your priority
- You've plateaued on semaglutide
- GI side effects concern you (tirzepatide may be gentler)
- Your insurance covers it, or you can access Zepbound
If cost and access are equal, Mounjaro/tirzepatide edges out on efficacy. If you're paying cash, compounded semaglutide may be the most affordable path. Work with your doctor and check your insurance first — the "best" drug is the one you can actually get and afford consistently.
Frequently Asked Questions
Clinical data suggests tirzepatide (Mounjaro) produces greater weight loss — 22.5% vs 14.9%. The SURMOUNT-5 head-to-head trial confirmed tirzepatide's superiority. However, both are effective and individual results vary.
Ozempic is FDA-approved for type 2 diabetes, not weight loss, but doctors frequently prescribe it off-label. Wegovy is the same drug (semaglutide) at a higher dose, approved for weight loss.
Without insurance: Ozempic ~$900–$1,200/mo, Mounjaro ~$1,000–$1,200/mo. With insurance, copays vary from $0–$300/mo. Both have manufacturer savings programs.
Both cause GI side effects: nausea, diarrhea, vomiting, constipation. Mounjaro may have slightly lower nausea rates. Both carry boxed warnings for thyroid C-cell tumors.
Yes, with your doctor's guidance. Start Mounjaro at its lowest dose (2.5 mg) after stopping Ozempic. Many patients switch when they plateau.
🛒 Recommended Products
Support your GLP-1 weight loss journey
Affiliate links — support HighPeptides at no extra cost.
Related Comparisons & Tools
Explore more GLP-1 resources